Search research articles
Contact Us
Filters
Showing results (321-330 of 344) with videos related to
Page
of 35
Sort By:
The Lancet. Oncology
|
December 22, 2023
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
Kohei Shitara, Sun Young Rha, Lucjan S Wyrwicz, et al.
Future Oncology (London, England)
|
March 15, 2023
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus
Yelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
Nature Medicine
|
February 12, 2024
Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer
Kohei Shitara, Kei Muro, Jun Watanabe, et al.
The Lancet. Oncology
|
January 14, 2022
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang, Li-Tzong Chen, Min-Hee Ryu, et al.
The Lancet. Oncology
|
February 6, 2019
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
Charles S Fuchs, Kohei Shitara, Maria Di Bartolomeo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 7, 2025
Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study
Kazumasa Yamamoto, Hideaki Bando, Toshihiro Misumi, et al.
Nature Immunology
|
September 2, 2020
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
Shogo Kumagai, Yosuke Togashi, Takahiro Kamada, et al.
Nature
|
March 24, 2022
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
Kohei Shitara, Jaffer A Ajani, Markus Moehler, et al.
JAMA Oncology
|
September 4, 2020
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara, Eric Van Cutsem, Yung-Jue Bang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2023
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
Manish A Shah, Erin B Kennedy, Ashley E Alarcon-Rozas, et al.
Page
of 35
Search research articles
Search
Showing results (321-330 of 344) with videos related to
Sort By:
Page
of 35
The Lancet. Oncology
|
December 22, 2023
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
Kohei Shitara, Sun Young Rha, Lucjan S Wyrwicz, et al.
Future Oncology (London, England)
|
March 15, 2023
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus
Yelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
Nature Medicine
|
February 12, 2024
Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer
Kohei Shitara, Kei Muro, Jun Watanabe, et al.
The Lancet. Oncology
|
January 14, 2022
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang, Li-Tzong Chen, Min-Hee Ryu, et al.
The Lancet. Oncology
|
February 6, 2019
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
Charles S Fuchs, Kohei Shitara, Maria Di Bartolomeo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 7, 2025
Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study
Kazumasa Yamamoto, Hideaki Bando, Toshihiro Misumi, et al.
Nature Immunology
|
September 2, 2020
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
Shogo Kumagai, Yosuke Togashi, Takahiro Kamada, et al.
Nature
|
March 24, 2022
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
Kohei Shitara, Jaffer A Ajani, Markus Moehler, et al.
JAMA Oncology
|
September 4, 2020
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara, Eric Van Cutsem, Yung-Jue Bang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2023
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
Manish A Shah, Erin B Kennedy, Ashley E Alarcon-Rozas, et al.
Page
of 35